POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference in New York on April 20, 2012 at 8:30 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO) A live audio webcast and replay of this presentation may be accessed at http://www.media-server.com/m/p/dnf5o64x and on the Transcept Investor webpage at www.transcept.com. About Transcept Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. Contact:Transcept Pharmaceuticals, Inc. Greg MannSr. Director, Corporate Communications(510) 215-3567 email@example.com SOURCE Transcept Pharmaceuticals, Inc.